30 closest matches · ranked by relevance
Tumors With CDK4/6 Pathway Activation
Primary: Number of Participants With Solid Tumor Response ≥ 16 Weeks for Based Upon Local Investigator Assessments — 0; 3; 16; 71 Participants
Non-small Cell Lung Cancer
Primary: Tumor Response by Direct RECIST Measurement — 0 participants
PI3K Pathway Activated Tumors
Primary: Participant Clinical Benefit Response Rate — 15.1 percentage of participants
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Metastatic Castration Resistant Prostate Cancer · Metastatic Cancer · Solid Tumor
Primary: The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment. — 2; 0 participants
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
Tumor Pathway Activations Inhibited by Dovitinib
Primary: Clinical Benefit Rate (CBR) — 0; 1; 10; 11 number of participants
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Breast Cancer
Primary: Number of Participants Classified According to Treatment Pattern — 30; NA; NA; NA Participants
Neoplasms · Solid Tumors · Biliary Cancer
Primary: Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator — 21.0; 19.5; 25.5; 33.3 Percentage of Participants
Oligodendroglioma · Oligoastrocytoma
Primary: Progression-free Survival (PFS) at Six Months (PFS6m) — 21 Percentage of participants
Sarcoma · Liposarcoma
Primary: Progression Free Survival at 12 Weeks — 66; 57.2 percentage of particpants
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Breast Cancer
Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Advanced Digestive System Neuroendocrine Neoplasm · Duodenal Neuroendocrine Tumor G1 · Functional Pancreatic Neuroendocrine Tumor
Primary: Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1 — 19 participants
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Advanced Gastrointestinal Stromal Tumors
Primary: Number of Participants With Non Progression at 4 Months — 3 Participants
CCND1 Gene Amplification · CCND2 Gene Amplification · CCND3 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 6 percentage of participants
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Metastatic Breast Cancer · Breast Carcinoma
Primary: Progression Free Survival (PFS) — 2.76; 5.29 months
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Advanced Metastatic Cancer · Advanced Prostate Cancer
Primary: Clinical Benefit Rate (CBR) of Nivolumab With or Without Ipilimumab — 1; 18; 1; 1 Participants
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Triple Negative Breast Cancer · Breast Cancer
Primary: Immune-based Mechanism of Action — 0.3 CD8+/Tregs ratio — p=0.101
Breast Cancer
Primary: Cohort A: Recommended Phase2 Dose (RP2D) — 400 mg
Breast Cancer
Primary: Phase Ib Primary Outcome: Proportion of Patients Who Experienced DLTs Attributable to Palbociclib, Tucatinib, or Both — 100; 65; 100 percentage of participants
Adult Solid Tumor · Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Response Rates — 4; 0; 0; 0 Participants